2 recruiting, 1 active not recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Prostate Cancer Metastatic Castration-Resistant: new trials by email Literature Review of Prostate Cancer Metastatic Castration-Resistant trials Research Report on Prostate Cancer Metastatic Castration-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| External Beam and Radioligand Radiotherapy for mCRPC External Beam Radiotherapy Delivered Between Cycles of Radioligand Radiotherapy, Standard of care 177Lutetium-PSMA - Prostate Cancer Metastatic Castration-Resistant | Phase 2 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 120 | 2026-07-07 | 2026-09-01 |
| Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) Sacituzumab Tirumotecan, Tagitanlimab - Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 28 | 2025-09-22 | 2025-09-18 |
| Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Olaparib, Abiraterone Acetate, Prednisone - Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair | Phase 2 | Active not recruiting | Northwestern University | 70 | 2017-01-12 | 2026-06-01 |
Prostatic Neoplasms (2) · Adenocarcinoma (1)
Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Carcinoma (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
18-O-demethylcervinomycin A2 (1) · Abiraterone Acetate (1) · Prednisone (1) · olaparib (1)
Centre hospitalier de l'Université de Montréal (CHUM) (1) · Northwestern University (1) · Tianjin Medical University Second Hospital (1)
Canada (1) · China (1) · United States (1)
Cynthia Menard, MD (1) · Haitao Wang, Ph.D (1) · Maha Hussain, MD, FACP, FASCO (1)